Aradigm Corporation

Equities

ARDMQ

US0385054004

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+6.73%	-25.81%

2020	Aradigm Corporation Went Out of Business	CI
2020	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Aradigm Corporation Filed for Bankruptcy

February 15, 2019 at 12:00 am EST

Aradigm Corporation filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Northern District of California on February 15, 2019. The debtor listed its assets of $3.76 million and liabilities of $27.22 million. The debtor is represented by Bennett G. Young of Jeffer Mangels Butler and Mitchell LLP as its legal counsel.

Latest news about Aradigm Corporation

Aradigm Corporation Went Out of Business	20-06-29	CI
Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	20-06-12	CI
Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	20-04-27	CI
Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	20-04-08	CI
Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	20-03-30	CI
Motion for Asset Sale Approved for Aradigm Corporation	20-03-30	CI
Bidding Procedure Approved for Aradigm Corporation	20-03-09	CI
Motion for Asset Sale Filed by Aradigm Corporation	20-02-20	CI
Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	20-02-20	CI
Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	19-11-05	CI
Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	19-10-30	CI
Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	19-10-21	CI
Motion for Exclusivity Period Extension Approved For Aradigm Corporation	19-07-19	CI
First Motion for Exclusivity Period Extension Filed by Aradigm Corporation	19-06-14	CI
DIP Financing Approved for Aradigm Corporation	19-06-06	CI
Aradigm Announces Receipt of Final FDA Minutes for the Type B Meeting on January 25, 2019	19-02-22	CI
Aradigm Corporation will Change its Ticker to ARDM.Q from ARDM	19-02-20	CI
Aradigm Corporation Announces Management Changes	19-02-19	CI
Aradigm Corporation Filed for Bankruptcy	19-02-15	CI
Aradigm Intends To Sell Assets	19-02-15	CI
Aradigm Corporation Announces Detailed Third Party Evaluation Results for Apulmiq/Linhaliq	19-01-16	CI
Aradigm Corporation(OTCPK:ARDM) dropped from S&P TMI Index	19-01-16	CI
Aradigm Corporation(OTCPK:ARDM.Q) dropped from NASDAQ Composite Index	19-01-15	CI
Aradigm Corporation announced that it has received $4 million in funding from Grifols Worldwide Operations Ltd.	19-01-01	CI
Aradigm Announces Results of Third Party Verification for Apulmiq	18-12-20	CI

Chart Aradigm Corporation

Duration

Period

More charts

Company Profile

Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARADIGM CORPORATION	-25.81%	702K
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research